Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jun 16;13(6):e060274.
doi: 10.1136/bmjopen-2021-060274.

Efficacy and safety of botulinum toxin for treating motor dysfunction in patients with Parkinson's disease: a systematic review and meta-analysis

Yuqi Yang  1   2 , Tong Zhang  3   2 , Lixu Liu  1   2 , Lei Shan  1   2 , Xueyan Hu  1   2 , Lingyu Yang  1   2 , Fei Gao  1   2 , Wu Xiaoli  1   2 , Hanzhi Li  1   2
Affiliations
Meta-Analysis

Efficacy and safety of botulinum toxin for treating motor dysfunction in patients with Parkinson's disease: a systematic review and meta-analysis

Yuqi Yang et al. BMJ Open. .

Abstract

Objective: To evaluate the efficacy and safety of botulinum toxin (BTX) for motor dysfunction in Parkinson's disease (PD).

Design: Systematic review and meta-analysis.

Data sources: Searches of PubMed, EMBASE and the Cochrane Library, from database inception to 20 October 2022.

Eligibility criteria: Studies reported in English with adult PD patients treated with BTX.

Data extraction and synthesis: Primary outcomes were United Parkinson's Disease Rate Scale Section (UPDRS) III (or its items) and Visual Analogue Scale (VAS). Secondary outcomes were UPDRS-II (or its items), Freezing of Gait Questionnaire (FOG-Q), Timed Up and Go test (TUG) and treatment-related adverse events (TRAEs). Mean difference (MD) or standardised MD (SMD) before and after treatment with 95% CIs were used for continuous variables and risk ratios (RRs) with 95% CIs was used for TRAEs.

Results: Six randomised controlled trials (RCTs) and six non-RCTs (case series) were included (ntotal=224 participants, nRCT=165). No significant difference was found in pooled results of UPDRS-III (available in four RCTs and two non-RCTs, SMD=-0.19, 95% CI -0.98 to 0.60), UPDRS-II (four RCTs and one non-RCT, SMD=-0.55, 95% CI -1.22 to 0.13), FOG-Q (one RCT and one non-RCT, SMD=0.53, 95% CI -1.93 to 2.98) or the risk of TRAEs (five RCTs, RR 0.87, 95% CI 0.37 to 2.01). Significant decreases were found in pooled VAS score (three RCTs and five non-RCTs, MD=-2.14, 95% CI -3.05 to -1.23) and TUG (MD=-2.06, 95% CI -2.91 to -1.20) after BTX treatment.

Conclusions: BTX may not be associated with motor symptoms alleviation, although it benefits pain alleviation and functional mobility improvement.

Keywords: NEUROPHYSIOLOGY; Neuropathology; Parkinson-s disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Meta-analysis of United Parkinson’s Disease Rate Scale Section III, by study design. IV, inverse-variance; RCT, randomised controlled trial.
Figure 2
Figure 2
Meta-analysis of VAS, by study design. IV, inverse-variance; RCT, randomised controlled trial; VAS, Visual Analogue Scale.
Figure 3
Figure 3
Meta-analysis of United Parkinson’s Disease Rate Scale Section II, by study design. IV, inverse-variance; RCT, randomised controlled trial.
Figure 4
Figure 4
Meta-analysis of TUG after BTX treatment. BTX, botulinum toxin; IV, inverse-variance; TUG, Timed Up and Go test.
Figure 5
Figure 5
Meta-analysis of TRAEs after BTX treatment. BTX, botulinum toxin; IV, inverse-variance; TRAEs, treatment-related adverse events.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pringsheim T, Jette N, Frolkis A, et al. . The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583–90. 10.1002/mds.25945 - DOI - PubMed
    1. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016;139 Suppl 1:318–24. 10.1111/jnc.13691 - DOI - PubMed
    1. Opara J, Małecki A, Małecka E, et al. . Motor assessment in Parkinson'S disease. Ann Agric Environ Med 2017;24:411–5. 10.5604/12321966.1232774 - DOI - PubMed
    1. Akbar U, Kurkchubasche AG, Friedman JH. Perioperative management of Parkinson’s disease. Expert Rev Neurother 2017;17:301–8. 10.1080/14737175.2017.1241143 - DOI - PubMed
    1. Raza C, Anjum R, Shakeel NUA. Parkinson's disease: mechanisms, Translational models and management strategies. Life Sci 2019;226:77–90. 10.1016/j.lfs.2019.03.057 - DOI - PubMed

Substances